214 related articles for article (PubMed ID: 36186000)
1. ASPM, CDC20, DLGAP5, BUB1B, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma.
Zhang Q; Wang Y; Xue F
Genet Res (Camb); 2022; 2022():3217248. PubMed ID: 36186000
[TBL] [Abstract][Full Text] [Related]
2. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
Front Oncol; 2021; 11():766947. PubMed ID: 34868993
[TBL] [Abstract][Full Text] [Related]
3. Combining Bioinformatics and Experiments to Identify and Verify Key Genes with Prognostic Values in Endometrial Carcinoma.
Zhang W; Gao L; Wang C; Wang S; Sun D; Li X; Liu M; Qi Y; Liu J; Lin B
J Cancer; 2020; 11(3):716-732. PubMed ID: 31942195
[TBL] [Abstract][Full Text] [Related]
4. Identification of cell division cycle 20 as a candidate biomarker and potential therapeutic target in bladder cancer using bioinformatics analysis.
Shen P; He X; Lan L; Hong Y; Lin M
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677673
[TBL] [Abstract][Full Text] [Related]
5. TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Yang Q; Yu B; Sun J
Biomed Res Int; 2020; 2020():4625123. PubMed ID: 33282948
[TBL] [Abstract][Full Text] [Related]
6. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
7. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
8. Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value.
Zhou Y; Yang L; Zhang X; Chen R; Chen X; Tang W; Zhang M
Biomed Res Int; 2019; 2019():6581576. PubMed ID: 31119182
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel key genes associated with uterine corpus endometrial carcinoma progression and prognosis.
Li H; Zhou Q; Wu Z; Lu X
Ann Transl Med; 2023 Jan; 11(2):100. PubMed ID: 36819577
[TBL] [Abstract][Full Text] [Related]
10. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
Miao C; Fang X; Chen Y; Zhao Y; Guo Q
Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
[TBL] [Abstract][Full Text] [Related]
11. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis.
Qiao Y; Yuan F; Wang X; Hu J; Mao Y; Zhao Z
Cancer Biomark; 2022; 35(2):227-243. PubMed ID: 36120772
[TBL] [Abstract][Full Text] [Related]
13. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
14. Identification of hub genes associated with bladder cancer using bioinformatic analyses.
Zheng W; Zhao Y; Wang T; Zhao X; Tan Z
Transl Cancer Res; 2022 May; 11(5):1330-1343. PubMed ID: 35706790
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
16. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
17. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
18. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
Zhang L; Sun L; Zhang B; Chen L
Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
[TBL] [Abstract][Full Text] [Related]
19. BUB1, BUB1B, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma.
Hao Q; Wu H; Liu E; Wang L
BMC Cancer; 2023 Oct; 23(1):995. PubMed ID: 37853361
[TBL] [Abstract][Full Text] [Related]
20. CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma.
Peng Q; Huang H; Zhu C; Hou Q; Wei S; Xiao Y; Zhang Z; Sun X
Oxid Med Cell Longev; 2022; 2022():8421813. PubMed ID: 36193067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
